BMY — Bristol-Myers Squibb Company

Is BMY overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - General

Overbought As of August 19, 2026

Bristol-Myers Squibb Company (BMY) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $67.61. The rating moved from Neutral to Overbought on August 12, 2026.

See all overbought Healthcare stocks →

AI analysis

Bristol-Myers Squibb exhibits the traits of a cash-generative, large-cap pharmaceutical business with a diversified commercial footprint and a meaningful oncology/immunology pipeline. The company benefits from scale, steady demand for core therapies, and a market environment that supports strategic M&A and partner-driven biologics growth. Near-term performance is likely to be range-bound absent catalysts, while medium-term upside hinges on successful label expansions, trial readouts, and portfolio moves. Key risks include payer-driven price pressure, patent loss on material products, and potential clinical or regulatory setbacks that could depress revenue and sentiment.

Key factors

  • Stable, diversified commercial portfolio with a long-duration cash driver in the anticoagulant franchise (co-marketed), supporting predictable free cash flow
  • Market-leading oncology and immunology capabilities with a deep pipeline that can deliver medium-term revenue upside via label expansions and new approvals
  • Defensive sector positioning that tends to hold value in risk-off environments, supported by steady payer demand for core therapies
  • Industry-wide M&A appetite and elevated biotech/pharma multiples increase the likelihood of strategic bolt-on deals or portfolio optimization that could unlock value
  • Operational scale and global commercial infrastructure enable efficient roll-out of new assets and lifecycle-management of existing products
  • Moderate exposure to favorable CRO/CDMO tailwinds as biologics and complex therapeutics demand increases, indirectly supporting partner pipelines and contract revenues

Risks

  • Payer margin pressure and Medicare/MA distribution changes that could compress realized prices or access for certain products
  • Patent expirations or generic competition for key revenue contributors that would materially reduce top-line growth
  • Regulatory or clinical setbacks in late-stage trials that could delay approvals or limit label expansion
  • Litigation, product safety issues, or supply-chain disruptions that can cause abrupt earnings volatility
  • Macroeconomic and interest-rate driven multiples compression that reduces valuation support for large-cap pharma
  • Limited near-term visibility in social and filings data (no fresh EDGAR comparisons or social-research signals in the provided window), increasing short-term uncertainty

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for BMY — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.